CD79A and hereditary spastic paraplegia: In 2012, the International Chapel Hill Consensus Conference (CHCC) replaced the eponym “HSP” with IgAV, because studies demonstrated that abnormal IgA deposition in the small vessel walls are the defining pathophysiologic feature (1).